Population Pharmacokinetic Analysis Proves Superiority of Continuous Infusion in PK/PD Target Attainment with Oxacillin in Staphylococcal Infections
Open Access
- 1 December 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (12) , 1736
Abstract
Considering its very short elimination half-life, the approved oxacillin dosage might not be sufficient to maintain the pharmacokinetic/pharmacodynamics (PK/PD) target of time-dependent antibiotics. This study aimed to describe the population pharmacokinetics of oxacillin and to explore the probability of PK/PD target attainment by using various dosing regimens with oxacillin in staphylococcal infections. Both total and unbound oxacillin plasma concentrations retrieved as a part of routine therapeutic drug-monitoring practice were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were used to generate the theoretical distribution of unbound oxacillin plasma concentration–time profiles at various dosage regimens. Data from 24 patients treated with oxacillin for staphylococcal infection have been included into the analysis. The volume of distribution of oxacillin in the population was 11.2 L, while the elimination rate constant baseline of 0.73 h−1 increased by 0.3 h−1 with each 1 mL/s/1.73 m2 of the estimated glomerular filtration rate (eGFR). The median value of oxacillin binding to plasma proteins was 86%. The superiority of continuous infusion in achieving target PK/PD values was demonstrated and dosing according to eGFR was proposed. Daily oxacillin doses of 9.5 g, 11 g, or 12.5 g administered by continuous infusion have been shown to be optimal for achieving target PK/PD values in patients with moderate, mild, or normal renal function, respectively.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (MH CZ-DRO-VFN64165)
- Univerzita Karlova v Praze
This publication has 10 references indexed in Scilit:
- Emergence of methicillin resistance predates the clinical use of antibioticsNature, 2022
- The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcomeJournal of Intensive Care, 2020
- A Population Pharmacokinetic Analysis of Continuous Infusion of Cloxacillin during Staphylococcus aureus Bone and Joint InfectionsAntimicrobial Agents and Chemotherapy, 2020
- Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimenInternational Journal of Antimicrobial Agents, 2019
- Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposuresJournal of Antimicrobial Chemotherapy, 2018
- Antibiotics Manual2017
- Antibiotic resistance in Staphylococcus aureus. Current status and future prospectsFEMS Microbiology Reviews, 2017
- β‐Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured reviewClinical and Experimental Pharmacology and Physiology, 2012
- Analysis of isoxazolyl penicillins and their metabolites in body fluids by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- Oxacillin Treatment of Severe Staphylococcal InfectionsNew England Journal of Medicine, 1963